US 11,834,504 B2
DARPin based multi-specific t-cell engagers
Nina Reschke, Schlieren (CH); Sebastian Grimm, Schlieren (CH); Christian Reichen, Schlieren (CH); Bernd Schlereth, Schlieren (CH); Victor Levitsky, Schlieren (CH); and Matteo Bianchi, Schlieren (CH)
Assigned to MOLECULAR PARTNERS AG, Schlieren (CH)
Filed by MOLECULAR PARTNERS AG, Schlieren (CH)
Filed on Mar. 9, 2022, as Appl. No. 17/654,209.
Claims priority of provisional application 63/265,184, filed on Dec. 9, 2021.
Claims priority of provisional application 63/172,973, filed on Apr. 9, 2021.
Claims priority of provisional application 63/158,539, filed on Mar. 9, 2021.
Prior Publication US 2023/0056271 A1, Feb. 23, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2809 (2013.01) [A61P 35/00 (2018.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2866 (2013.01); C07K 16/2875 (2013.01); C07K 2317/31 (2013.01); C07K 2318/00 (2013.01); C07K 2319/00 (2013.01)] 21 Claims
 
1. A recombinant protein comprising (1) a first binding agent that specifically binds to a protein expressed on the surface of an immune cell, and (2) at least two binding agents that specifically bind to a tumor-associated antigen, wherein said two binding agents specifically bind to different tumor-associated antigens, and wherein said first binding agent is a designed ankyrin repeat domain with binding specificity for CD3, and wherein said ankyrin repeat domain with binding specificity for CD3 comprises an amino acid sequence that is at least 85% identical to any one of the amino acid sequences of SEQ ID NOs: 1 to 5.